143 related articles for article (PubMed ID: 38330545)
21. Off-label use of rituximab in 196 patients with severe, refractory systemic autoimmune diseases.
Ramos-Casals M; García-Hernández FJ; de Ramón E; Callejas JL; Martínez-Berriotxoa A; Pallarés L; Caminal-Montero L; Selva-O'Callaghan A; Oristrell J; Hidalgo C; Pérez-Alvarez R; Micó ML; Medrano F; Gómez de la Torre R; Díaz-Lagares C; Camps M; Ortego N; Sánchez-Román J;
Clin Exp Rheumatol; 2010; 28(4):468-76. PubMed ID: 20525449
[TBL] [Abstract][Full Text] [Related]
22. Low-dose interleukin-2 selectively corrects regulatory T cell defects in patients with systemic lupus erythematosus.
von Spee-Mayer C; Siegert E; Abdirama D; Rose A; Klaus A; Alexander T; Enghard P; Sawitzki B; Hiepe F; Radbruch A; Burmester GR; Riemekasten G; Humrich JY
Ann Rheum Dis; 2016 Jul; 75(7):1407-15. PubMed ID: 26324847
[TBL] [Abstract][Full Text] [Related]
23. IL-38: A New Player in Inflammatory Autoimmune Disorders.
Xie L; Huang Z; Li H; Liu X; Zheng S; Su W
Biomolecules; 2019 Aug; 9(8):. PubMed ID: 31387327
[TBL] [Abstract][Full Text] [Related]
24. Pathogenesis and novel therapeutics of regulatory T cell subsets and interleukin-2 therapy in systemic lupus erythematosus.
Tsai YG; Liao PF; Hsiao KH; Wu HM; Lin CY; Yang KD
Front Immunol; 2023; 14():1230264. PubMed ID: 37771588
[TBL] [Abstract][Full Text] [Related]
25. A randomized double-blind placebo-controlled trial of low-dose interleukin-2 in relapsing-remitting multiple sclerosis.
Louapre C; Rosenzwajg M; Golse M; Roux A; Pitoiset F; Adda L; Tchitchek N; Papeix C; Maillart E; Ungureanu A; Charbonnier-Beaupel F; Galanaud D; Corvol JC; Vicaut E; Lubetzki C; Klatzmann D
J Neurol; 2023 Sep; 270(9):4403-4414. PubMed ID: 37245191
[TBL] [Abstract][Full Text] [Related]
26. Blocking IL-17: A Promising Strategy in the Treatment of Systemic Rheumatic Diseases.
Rafael-Vidal C; Pérez N; Altabás I; Garcia S; Pego-Reigosa JM
Int J Mol Sci; 2020 Sep; 21(19):. PubMed ID: 32993066
[TBL] [Abstract][Full Text] [Related]
27. Low-Dose IL-2 in the Treatment of Lupus.
Mizui M; Tsokos GC
Curr Rheumatol Rep; 2016 Nov; 18(11):68. PubMed ID: 27734211
[TBL] [Abstract][Full Text] [Related]
28. Concomitant use of interleukin-2 and tacrolimus suppresses follicular helper T cell proportion and exerts therapeutic effect against lupus nephritis in systemic lupus erythematosus-like chronic graft versus host disease.
Nasa Y; Satake A; Tsuji R; Saito R; Tsubokura Y; Yoshimura H; Ito T
Front Immunol; 2024; 15():1326066. PubMed ID: 38665907
[TBL] [Abstract][Full Text] [Related]
29. Low-dose interleukin-2 therapy in refractory systemic lupus erythematosus: an investigator-initiated, single-centre phase 1 and 2a clinical trial.
Humrich JY; von Spee-Mayer C; Siegert E; Bertolo M; Rose A; Abdirama D; Enghard P; Stuhlmüller B; Sawitzki B; Huscher D; Hiepe F; Alexander T; Feist E; Radbruch A; Burmester GR; Riemekasten G
Lancet Rheumatol; 2019 Sep; 1(1):e44-e54. PubMed ID: 38229359
[TBL] [Abstract][Full Text] [Related]
30. Low-dose interleukin-2 therapy: a driver of an imbalance between immune tolerance and autoimmunity.
Kosmaczewska A
Int J Mol Sci; 2014 Oct; 15(10):18574-92. PubMed ID: 25322151
[TBL] [Abstract][Full Text] [Related]
31. Efficacy and safety of low-dose IL-2 in the treatment of systemic lupus erythematosus: a randomised, double-blind, placebo-controlled trial.
He J; Zhang R; Shao M; Zhao X; Miao M; Chen J; Liu J; Zhang X; Zhang X; Jin Y; Wang Y; Zhang S; Zhu L; Jacob A; Jia R; You X; Li X; Li C; Zhou Y; Yang Y; Ye H; Liu Y; Su Y; Shen N; Alexander J; Guo J; Ambrus J; Lin X; Yu D; Sun X; Li Z
Ann Rheum Dis; 2020 Jan; 79(1):141-149. PubMed ID: 31537547
[TBL] [Abstract][Full Text] [Related]
32. Increased sensitivity of Treg cells from patients with PBC to low dose IL-12 drives their differentiation into IFN-γ secreting cells.
Liaskou E; Patel SR; Webb G; Bagkou Dimakou D; Akiror S; Krishna M; Mells G; Jones DE; Bowman SJ; Barone F; Fisher BA; Hirschfield GM
J Autoimmun; 2018 Nov; 94():143-155. PubMed ID: 30119881
[TBL] [Abstract][Full Text] [Related]
33. Novel and potential future therapeutic options in systemic autoimmune diseases.
Balogh L; Oláh K; Sánta S; Majerhoffer N; Németh T
Front Immunol; 2024; 15():1249500. PubMed ID: 38558805
[TBL] [Abstract][Full Text] [Related]
34. Interferon Inhibition for Lupus with Anifrolumab: Critical Appraisal of the Evidence Leading to FDA Approval.
Loncharich MF; Anderson CW
ACR Open Rheumatol; 2022 Jun; 4(6):486-491. PubMed ID: 35157371
[TBL] [Abstract][Full Text] [Related]
35. The Next Frontier of Regulatory T Cells: Promising Immunotherapy for Autoimmune Diseases and Organ Transplantations.
Terry LV; Oo YH
Front Immunol; 2020; 11():565518. PubMed ID: 33072105
[TBL] [Abstract][Full Text] [Related]
36. Fc receptors gone wrong: A comprehensive review of their roles in autoimmune and inflammatory diseases.
Chalayer E; Gramont B; Zekre F; Goguyer-Deschaumes R; Waeckel L; Grange L; Paul S; Chung AW; Killian M
Autoimmun Rev; 2022 Mar; 21(3):103016. PubMed ID: 34915182
[TBL] [Abstract][Full Text] [Related]
37. IL-2-based approaches to Treg enhancement.
Harris F; Berdugo YA; Tree T
Clin Exp Immunol; 2023 Mar; 211(2):149-163. PubMed ID: 36399073
[TBL] [Abstract][Full Text] [Related]
38. Anti-Ro52/TRIM21 antibodies are associated with aberrant inflammatory circuits in patients with systemic autoimmune rheumatic diseases.
Amezcua-Guerra LM; Pérez-García LF; Jiménez-Rojas V; Márquez-Velasco R; Silveira LH
Gac Med Mex; 2023; 159(1):55-64. PubMed ID: 36930561
[TBL] [Abstract][Full Text] [Related]
39. A single-agent fusion of human IL-2 and anti-IL-2 antibody that selectively expands regulatory T cells.
Lin Y; Wang X; Qin Y; Wang C; Zhou T; Zhang L; Su L; Ren W; Liao C
Commun Biol; 2024 Mar; 7(1):299. PubMed ID: 38461332
[TBL] [Abstract][Full Text] [Related]
40. Protocol of the adaptive study of IL-2 dose frequency on regulatory T cells in type 1 diabetes (DILfrequency): a mechanistic, non-randomised, repeat dose, open-label, response-adaptive study.
Truman LA; Pekalski ML; Kareclas P; Evangelou M; Walker NM; Howlett J; Mander AP; Kennet J; Wicker LS; Bond S; Todd JA; Waldron-Lynch F
BMJ Open; 2015 Dec; 5(12):e009799. PubMed ID: 26646829
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
